INDP

Indaptus Therapeutics Inc

Add to Watchlist

Advanced Chart

9.890

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.890

Open

9.890

VWAP

9.89

Vol

608.00

Mkt Cap

5.66M

Low

9.890

Amount

6.01K

EV/EBITDA(TTM)

Total Shares

8.54M

2.10M

EV/OCF(TTM)

P/S(TTM)

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

1 Analyst Rating

-79.78% Downside

Wall Street analysts forecast INDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDP is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

-79.78% Downside

Current: 9.890

Low

2.00

Averages

2.00

High

2.00

-79.78% Downside

Current: 9.890

Low

2.00

Averages

2.00

High

2.00

Maxim Group

Jason McCarthy

Strong Buy

Maintains

$8 → $5

2024-11-13

Reason

Maxim Group

Jason McCarthy

Price Target

$8 → $5

2024-11-13

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$12

2024-10-16

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$12

2024-10-16

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Indaptus Therapeutics Inc (INDP.O) is -0.30, compared to its 5-year average forward P/E of -1.21. For a more detailed relative valuation and DCF analysis to assess Indaptus Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.21

Current PE

-0.30

Overvalued PE

-0.55

Undervalued PE

-1.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00